INFORMATION BY CANCER TYPE
Dr Shannon Westin, a clinical investigator at the MD Anderson Cancer Center, discusses PARP inhibition for patients with deleterious or suspected deleterious germline BRCA-mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
Studies have shown that African American women tend to have worse outcomes after ovarian cancer surgery than their white counterparts.
The pharmaceutical company Clovis Oncology filed a supplemental new drug application (sNDA) to the FDA for their drug Rubraca (rucaparib) to be used as maintenance therapy for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
Rebecca Arend, M.D., gynecologic oncologist at University of Alabama at Birmingham Hospital, discusses the rapidly changing field of ovarian cancer.
To better understand ovarian cancer, as well as predict when women might relapse, it is crucial that researchers start investigating more of the molecular phases of the disease, says Peter Dottino, M.D.
For patients with metastatic cancer, NED times are often overshadowed by their lurking disease waiting to pounce and return. Here are some thoughts on living life passionately, both during treatment and while NED
PARP inhibitors are changing the way ovarian cancer is treated.
More research is needed on the other genetic mutations, besides BRCA, that patients with ovarian cancer harbor so that they can be used to help plan treatments.
Some moments in life get seared into your brain. Years later you can picture exactly what you were wearing. You can conjure up the smell of the room.
Mail-order kits are now making genetic testing more accessible to patients who may need it the most.
The future for immunotherapy treatment for gynecologic cancers may be found in drug combinations, according to Dmitriy Zamarin, M.D., Ph.D., who admits that these agents have been slower to demonstrate progress in this group of patients.
Search Cancer Drugs & Terms
Information about treatment, including surgery, chemotherapy, radiation therapy, immunotherapy, and vaccine therapy
Ovarian Epithelial Cancer Treatment (PDQ®)
Expert-reviewed information summary about the treatment of ovarian epithelial cancer.
Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®)
Expert-reviewed information summary about the treatment of ovarian epithelial, fallopian tube, and primary peritoneal cancer treatment.
Ovarian Germ Cell Tumors Treatment (PDQ®)
Expert-reviewed information summary about the treatment of ovarian germ cell tumors.
Ovarian Low Malignant Potential Tumors Treatment (PDQ®)
Expert-reviewed information summary about the treatment of ovarian low-malignant potential tumors.
Prevention, Genetics, Causes
Information related to prevention, genetics, risk factors
Ovarian Cancer Prevention (PDQ®)
Expert-reviewed information summary about factors that may influence the risk of developing ovarian cancer and about research aimed at the prevention of this disease.
Screening and Testing
Information about methods of cancer detection including new imaging technologies, tumor markers, and biopsy procedures
Ovarian Cancer Screening (PDQ®)
Expert-reviewed information summary about tests used to detect or screen for ovarian cancer.